Influenza Diagnostics Market by Test Type {[Traditional (RIDT, Direct Fluorescent Antibody, Viral Culture, Serology), Molecular [RT-PCR, INAAT (NASBA, LAMP)]}, End User (Hospitals, Laboratories, Academics, Research Institutes) - Global Forecast to 2027

  • Report ID:MRHC - 104401
  • Pages: 169
  • Jun 2020
  • Formats*: PDF
  • Category: Healthcare
  • Delivery: 2 to 4 Hours

1. Introduction
    1.1. Market Definition
    1.2. Market Ecosystem
    1.3. Currency

2. Research Methodology
    2.1. Research Process
    2.2. Data Collection & Validation
           2.2.1. Secondary Research
           2.2.2. Primary Research
    2.3. Market Assessment
           2.3.1. Market Size Estimation
                    2.3.1.1. Bottom-Up Approach
                    2.3.1.2. Top-Down Approach
                    2.3.1.3. Growth forecast
           2.3.2. Market Share Analysis
    2.4. Assumptions for the Study
    2.5. Limitations for the Study

3. Executive Summary
4. Market Insights
    4.1. Market Overview
    4.2. Drivers
           4.2.1. Increasing Global Prevalence of Influenza
           4.2.2. Growing Awareness of Early Influenza Diagnosis
           4.2.3. Development of CLIA-Waived POC Molecular Influenza Tests
           4.2.4. Shift in Focus from Centralized Laboratories to Point-of-Care Testing Services
    4.3. Restraints
           4.3.1. Technical Requirements and Regulatory Process for High or Moderate Complexity Tests
    4.4. Opportunities
           4.4.1. Advances in Genomics and Proteomics
           4.4.2. Growth Opportunities in Emerging Economies
    4.5. Challenges
           4.5.1. Unfavorable and Inadequate Reimbursement Scenario
    4.6. Impact of Covid-19 Pandemic

5. Global Influenza Diagnostics Market, by Test Type
    5.1. Introduction
    5.2. Traditional Diagnostic Tests
           5.2.1. Rapid Influenza Diagnostics Test (RIDT)
           5.2.2. Direct Fluorescent Antibody (DFA) Tests
           5.2.3. Viral Culture
           5.2.4. Serological Assays
    5.3. Molecular Diagnostic Tests
           5.3.1. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
           5.3.2. Isothermal Nucleic Acid Amplification Tests (INAAT)
                    5.3.2.1. Loop Mediated Isothermal Based Amplification Assays
                    5.3.2.2. Transcription Mediated Isothermal Based Amplification Assays
                    5.3.2.3. Nucleic Acid Sequence-Based Amplification Tests
                    5.3.2.4. Other Isothermal Nucleic Acid Amplification Assays
           5.3.3. Other Molecular Diagnostic Tests

6. Global Influenza Diagnostics Market, by End User
    6.1. Introduction
    6.2. Hospital & Clinical Laboratories
    6.3. Diagnostic Reference Laboratories
    6.4. Academic/Research Institutes
    6.5. Other End Users

7. Global Influenza Diagnostics Market, by Geography
    7.1. Introduction
    7.2. North America
           7.2.1. U.S.
           7.2.2. Canada
    7.3. Europe
           7.3.1. Germany
           7.3.2. France
           7.3.3. U.K.
           7.3.4. Italy
           7.3.5. Spain
           7.3.6. Rest of Europe
    7.4. Asia-Pacific
           7.4.1. China
           7.4.2. Japan
           7.4.3. India
           7.4.4. Rest of Asia-Pacific
    7.5. Latin America
    7.6. Middle East & Africa

8. Competitive Landscape
    8.1. Introduction
    8.2. Key Growth Strategies
    8.3. Competitive Benchmarking
    8.4. Market Share Analysis (2019)
           8.4.1. F. Hoffmann-La Roche Ltd
           8.4.2. Quidel Corporation
           8.4.3. Thermo Fisher Scientific, Inc.
           8.4.4. Abbott Laboratories
           8.4.5. Other Companies

9. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
    9.1. Thermo Fisher Scientific, Inc.
    9.2. Abbott Laboratories
    9.3. Danaher Corporation
    9.4. Bio-Rad Laboratories, Inc.
    9.5. BioMérieux S.A.
    9.6. F. Hoffmann-La Roche Ltd.
    9.7. Becton, Dickinson and Company
    9.8. Meridian Bioscience, Inc.
    9.9. Quidel Corporation
    9.10. Hologic, Inc.
    9.11. Siemens Healthineers AG (Subsidiary of Siemens AG)
    9.12. Luminex Corporation
    9.13. GenMark Diagnostics, Inc.
    9.14. Altona Diagnostics GmbH
    9.15. SA Scientific, Ltd.
    9.16. Sekisui Diagnostics, LLC
    9.17. CorisBioconcept SPRL
    9.18. ELITech Group
    9.19. Mast Group, Ltd.
    9.20. Response Biomedical Corporation
    9.21. Germaine Laboratories, Inc.    

10. Appendix
      10.1. Questionnaire
      10.2. Available Customization

List of Tables 
Table 1 Global Influenza Diagnostics Market Drivers: Impact Analysis (2020-2027)
Table 2 Europe: Percentage of Specimens Positive for Influenza, 2015-2020
Table 3 Global Influenza Diagnostics Market Restraint: Impact Analysis (2020-2027)
Table 4 Some Clinical Applications of Influenza Genomics and Proteomics
Table 5 COVID 19 Confirmed Cases and Deaths across the World (27th May 2020)
Table 6 Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($ Million)
Table 7 Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 8 Traditional Influenza Diagnostic Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 9 Advantages & Disadvantages of RIDT
Table 10 RIDTs Market Size, by Country/Region, 2018-2027 ($Million)
Table 11 Direct Fluorescent Antibody Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 12 Viral Culture Market Size, by Country/Region, 2018-2027 ($Million)
Table 13 Serological Assays Market Size, by Country/Region, 2018-2027 ($Million)
Table 14 Molecular Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 15 Molecular Influenza Diagnostic Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 16 Comparison of RT-PCR with Traditional Diagnostic Tests
Table 17 RT-PCR Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 18 INAAT Based Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 19 INAAT Based Influenza Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 20 Loop-Mediated Isothermal Amplification (Lamp) Assays Market Size, by Country/Region, 2018-2027 ($Million)
Table 21 Transcription Mediated Isothermal Based Amplification Assays Market Size, by Country/Region, 2018-2027 ($Million)
Table 22 Nucleic Acid Sequence-Based Amplification Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 23 Other INAAT Assays Market Size, by Country/Region, 2018-2027 ($Million)
Table 24 Other Molecular Influenza Diagnostic Tests Market Size, by Country/Region, 2018-2027 ($Million)
Table 25 Influenza Diagnostics Market Size, by End User, 2018-2027 ($ Million)
Table 26 Influenza Diagnostics Market Size for Hospital & Clinical Laboratories, by Country/Region, 2018-2027 ($ Million)
Table 27 Influenza Diagnostics Market Size for Diagnostic Reference Laboratories, by Country/Region, 2018-2027 ($Million)
Table 28 Influenza Diagnostics Market Size for Academics/Research Institutes, by Country/Region, 2018-2027 ($Million)
Table 29 Influenza Diagnostics Market Size for Other End Users, by Country/Region, 2018-2027 ($Million)
Table 30 Influenza Diagnostics Market Size, by Country/Region, 2018-2027 ($Million)
Table 31 North America: Influenza Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 32 North America: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 33 North America: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 34 North America: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 35 North America: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 36 North America: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 37 U.S.: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 38 U.S.: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 39 U.S.: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 40 U.S.: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 41 U.S.: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 42 Canada: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 43 Canada: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 44 Canada: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 45 Canada: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 46 Canada: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 47 Europe: Influenza Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 48 Europe: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 49 Europe: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 50 Europe: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 51 Europe: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 52 Europe: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 53 Germany: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 54 Germany: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 55 Germany: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 56 Germany: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 57 Germany: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 58 France: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 59 France: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 60 France: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 61 France: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 62 France: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 63 Number of Acute Respiratory Illness Outbreaks in the U.K. by Institution Type: 2015-2019
Table 64 U.K.: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 65 U.K.: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 66 U.K.: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 67 U.K.: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 68 U.K.: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 69 Italy: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 70 Italy: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 71 Italy: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 72 Italy: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 73 Italy: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 74 Spain: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 75 Spain: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 76 Spain: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 77 Spain: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 78 Spain: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 79 Rest of Europe: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 80 Rest of Europe: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 81 Rest of Europe: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 82 Rest of Europe: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 83 Rest of Europe: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 84 Asia-Pacific: Influenza Diagnostics Market Size, by Country, 2018-2027 ($Million)
Table 85 Asia-Pacific: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 87 Asia-Pacific: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 88 Asia-Pacific: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 89 Asia-Pacific: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 90 China: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 91 China: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 92 China: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 93 China: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 94 China: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 95 Japan: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 96 Japan: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 97 Japan: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 98 Japan: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 99 Japan: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 100 India: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 101 India: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 102 India: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 103 India: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 104 India: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 105 Rest of Asia-Pacific: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 106 Rest of Asia-Pacific: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 107 Rest of Asia-Pacific: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 108 Rest of Asia-Pacific: Isothermal Nucleic Acid Amplification Tests Market Size, 2018-2027 ($Million)
Table 109 Rest of Asia-Pacific: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 110 Latin America: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 111 Latin America: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 112 Latin America: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 113 Latin America: Isothermal Nucleic Acid Amplification Tests Market Size, by Type, 2018-2027 ($Million)
Table 114 Latin America: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 115 Middle East & Africa: Influenza Diagnostics Market Size, by Test Type, 2018-2027 ($Million)
Table 116 Middle East & Africa: Traditional Influenza Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 117 Middle East & Africa: Molecular Diagnostic Tests Market Size, by Type, 2018-2027 ($Million)
Table 118 Middle East & Africa: Isothermal Nucleic Acid Amplification Tests Market Size, 2018-2027 ($Million)
Table 119 Middle East & Africa: Influenza Diagnostics Market Size, by End User, 2018-2027 ($Million)
Table 120 Recent Developments, by Company, 2017-2020

List of Figures 

Figure 1 Key Stakeholders
Figure 2 Research Process
Figure 3 Key Secondary Sources
Figure 4 Primary Research Techniques
Figure 5 Key Executives Interviewed
Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 7 Market Size Estimation
Figure 8 Global Influenza Diagnostics Market, by Test Type, 2020 Vs 2027 ($Million)
Figure 9 Global Influenza Diagnostics Market Overview, by End User, 2020-2027 ($Million)
Figure 10 Regional Snapshot: Influenza Diagnostics Market
Figure 11 Market Dynamics
Figure 12 Global Influenza Transmission Zone
Figure 13 U.S. Influenza Burden (2010-2018)
Figure 14 Global Influenza Diagnostics Market Size, by Test Type, 2020-2027 ($Million)
Figure 15 Global Influenza Diagnostics Market Size, by End User, 2020-2027 ($Million)
Figure 16 Global Influenza Diagnostics Market Size, by Geography, 2020-2027 ($Million)
Figure 17 North America: Influenza Diagnostics Market Snapshot
Figure 18 Population Aged 65 or above (As % of total Population) in the U.S.:2012-2018
Figure 19 Europe: Influenza Diagnostics Market Snapshot
Figure 20 Healthcare Spending Per Capita in France: 2015-2018
Figure 21 Proportion of Population Aged 65 or Above (As % of total Population)
Figure 22 Influenza Cases in Spain per 100,000 Inhabitants: 2015-2019
Figure 23 Per Capita Health Spending by Country, 2018 ($)
Figure 24 Asia-Pacific: Influenza Diagnostics Snapshot
Figure 25 Number of Geriatric Population (Aged 65 & Above) In China: 2010-2050(In Millions)
Figure 26 Number of Swine Flu Cases in India: 2012-2018
Figure 27 Population Aged 60 & Above In Latin America: 2000-2050 (In Millions)
Figure 28 Key Growth Strategies Adopted by Leading Players, 2017-2020
Figure 29 Influenza Diagnostics Market: Competitive Benchmarking
Figure 30 Global Influenza Diagnostics Market Share Analysis, by Key Players, 2019 (%)
Figure 31 thermo Fisher Scientific, Inc.: Financial Overview (2019)
Figure 32 Abbott Laboratories: Financial Overview (2019)
Figure 33 Danaher Corporation: Financial Overview (2019)
Figure 34 Bio-Rad Laboratories, Inc.: Financial Overview (2019)
Figure 35 BioMérieux S.A.: Financial Overview (2018)
Figure 36 F. Hoffmann-La Roche Ltd: Financial Overview (2019)
Figure 37 Becton, Dickinson and Company: Financial Overview (2019)
Figure 38 Meridian Bioscience, Inc.: Financial Overview (2019)
Figure 39 Quidel Corporation: Financial Overview (2019)
Figure 40 Hologic, Inc.: Financial Overview (2019)
Figure 41 Siemens Healthineers Ag: Financial Overview (2019)
Figure 42 Luminex Corporation: Financial Overview (2019)
Figure 43 GenMark Diagnostics, Inc.: Financial Overview (2019)

COVID-19

This report provides pre & post COVID-19 market estimates

Download sample here

The influenza diagnostics market is expected to grow at a CAGR of 7.9% from 2020 to 2027 to reach at $1.17 billion by 2027. Influenza, which is commonly known as "the flu", is an infectious disease caused by an influenza virus. Various traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Nowadays, advanced technologies provide highly effective and accurate diagnosis of the influenza. For instance, the reverse transcription-polymerase chain reaction (RT-PCR), or real time, molecular test affords detection of influenza genetic material. Moreover, continued advancements in rapid influenza diagnostic testing (RIDT) has made this method an effective one for diagnosis because of its fast results and ease of specimen collection. The factors such as increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing are expected to propel the growth of the global influenza diagnostics market.

Furthermore, technical requirements & regulatory process for high or moderate tests may hinder the growth of the overall influenza diagnostics market during the forecast period.

Impact of COVID-19 on the Influenza Diagnostics Market

The rising burden of infectious diseases across the globe has increased the demand for infectious disease diagnosis products, including influenza & other diseases. The recent outbreak of the coronavirus disease (COVID-19), which has emerged since December 2019 in Wuhan, China, has caused destruction in several countries across the world. According to the WHO, as of 1st June 2020, there were 6,057,853 confirmed cases and 371,166 confirmed deaths. During this pandemic, it is important to minimize the spread of the disease by early diagnosis.

When compared to influenza with COVID-19, both viruses have a similar disease presentation i.e. they both cause respiratory issues. Moreover, both are transmitted by contact, droplets, and fomites. At earlier stages, COVID-19 patients are misdiagnosed with influenza and due to which its demand has raised in late 2019. However, soon it was realized that factors such as immunity, age group, transmission rate, vaccination, & few others are drastically different in case of COVID-19 & influenza. Thus, after realizing the difference between these two infections, the demand for influenza kits was normalized and the need for a comprehensive approach for diagnosis & treatment has gained importance to combat COVID-19 pandemic.

                                        Click here to: Get Free Request Sample Pages of this report

Growing awareness of early influenza diagnosis to drive the growth of the influenza diagnostics market

Early diagnosis of influenza leads to a better treatment and future care. Early diagnosis helps medical professionals and patients to take up various important medical decisions in terms of care and support. There exist a large number of advantages to obtain accurate and early diagnosis after noticing the cognitive symptoms related to a particular medical condition. Laboratory examination is one of the very effective and popularly practiced testing techniques for the diagnosis of various infectious diseases associated with bacterial, viral, or protozoal infections. Immunoassays, biochemical characterization, polymerase chain reaction, isothermal nucleic acid amplification test, and next-generation sequencing are performed to identify a comprehensive range of infectious diseases. 

The increasing awareness among the global population regarding the importance of early disease detection is a major factor responsible for the growth of the global influenza diagnostics market. Owing to this, organizations are taking initiatives to promote early diagnosis practice to prevent and eradicate mortality due to the disease. For instance:

  • In 2019, Public Health England (PHE) launched a 5-year (2020 to 2025) infectious disease strategy (which includes influenza) to prevent, detect, respond, and reduce the impact of infectious diseases. 
  • The WHO designed the Global Influenza Strategy 2019-2030 with the goal of reducing the burden of seasonal influenza, minimizing the risk of zoonotic diseases, and mitigating the impact of the influenza pandemic. Moreover, this strategy strengthened global influenza surveillance, monitoring, and data utilization, which expanded seasonal influenza prevention and control policies & programs to protect the vulnerable and promoted research activities for improving diagnostics, vaccines, and treatments against influenza.

Thus, the rising concerns with regards to the early diagnosis of influenza are accelerating the adoption of diagnostic products.

Key Findings in the Global Influenza Diagnostics Study:

Traditional diagnostics tests to command the largest share of the overall influenza diagnostics market in 2020

Based on test type, the traditional diagnostics segment is estimated to command the largest share of the overall influenza diagnostics market in 2020. The large share of this segment is primarily attributed to the wide use of rapid influenza diagnostics tests (RIDTs) due to its cost-effectiveness and ability to provide test results in 15– 30 minutes. In addition, the availability of advanced diagnostic immunoassay formats and increasing usage of miniaturized devices in influenza diagnostics are further stimulating the growth of this segment.

Hospitals & clinical laboratories segment to dominate the influenza diagnostics market in 2020

On the basis of end user, the hospitals & clinical laboratories segment is estimated to dominate the market in 2020, due to the increasing number of outpatient visits for influenza diseases, increasing hospital expenditures, and growing technological advancement for diagnostic platforms in hospitals.

Asia Pacific: The fastest growing market

At regional level, influenza diagnostics market is estimated to be dominated by the North America in 2020. On the other hand, the Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period, which is mainly attributed to the increasing number of influenza incidence, rising aging population, increasing focus of key vendors in the diagnostics market on this region, favorable reimbursement scenario for diagnostic procedures, increasing government investments to support the healthcare sector, improving infrastructure & accessibility to healthcare, and rising demand for better healthcare.

Key Players

The report includes competitive landscape based on extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in the industry over the past 4 years (2017-2020). The key players profiled in the global influenza diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Meridian Bioscience Inc. (U.S.),bioMérieux SA (France), Luminex Corporation (U.S.), Siemens Healthineers AG (Germany), GenMark Diagnostics, Inc. (U.S.), Sekisui Diagnostics, LLC (U.S.), altona Diagnostics GmbH (Germany), SA Scientific, Ltd. (U.S.), and ELITech Group (France), Coris Bioconcept SPRL (Belgium), and Mast Group Ltd.(U.K.).

Scope of the Report:

Market by Test Type

  • Traditional Diagnostic Tests
    • Rapid influenza diagnostic tests (RIDTs
    • Direct Fluorescent Antibody (DFA) Tests
    • Viral Culture
    • Serological Assays
  • Molecular Diagnostic Tests
    • Reverse Transcription Polymerase Chain Reaction (RT-PCR)
    • Isothermal Nucleic Acid Amplification Tests (INAAT)
      • Loop Mediated Isothermal Based Amplification Assays
      • Transcription Mediated Isothermal Based Amplification Assays
      • Transcription Mediated Isothermal Based Amplification Assays
      • Other Isothermal Nucleic Acid Amplification Tests
    • Other Molecular Diagnostic Tests

Market by End User

  • Hospitals & Clinical Laboratories
  • Diagnostic Reference Laboratories
  • Academic/Research Institutes
  • Other End Users

Market by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Key questions answered in the report-

The global influenza diagnostics is projected to reach $1.17 billion by 2027, at a CAGR of 7.9% during the forecast period of 2020-2027
Based on test type, the traditional diagnostics tests segment is estimated to account for the largest share of the global influenza diagnostics market in 2020, due to its advantages of cost-effectiveness and ability to provide test results, availability of advanced diagnostic immunoassay formats, and increasing usage of miniaturized devices in influenza diagnostics. On the other hand, the molecular diagnostic tests segment is expected to grow at the fastest CAGR of during the forecast period.
The diagnostic reference laboratories segment is projected to register the fastest CAGR during the forecast period, mainly due to their nature of supporting the diagnosis required in patient care as well as medical research. Moreover, owing to curtailed reimbursements for laboratory testing services, hospitals prefer to outsource their diagnostic testing services to the large commercial laboratories and eliminate associated operational expenses required for maintaining in-house labs, thereby driving the market.
Increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing are driving the growth of the market. Moreover, advances in genomics and proteomics and emerging markets such as India, Brazil, China, and others provide significant growth opportunities for vendors across the globe.
The global influenza diagnostics market is largely fragmented in nature and the key players, namely F. Hoffmann-La Roche Ltd (Switzerland), Quidel Corporation (U.S.), Abbott Laboratories (U.S.), and Thermo Fisher Scientific (U.S.), are majorly driving the innovation trends in the market with their strategic developments.
The prominent players operating in this market are Thermo Fisher Scientific Inc. (U.S.), Hologic, Inc. (U.S.), Quidel Corporation (U.S.), F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), Meridian Bioscience Inc. (U.S.),bioMérieux SA (France), Luminex Corporation (U.S.), Siemens Healthineers AG (Germany), GenMark Diagnostics, Inc. (U.S.), Sekisui Diagnostics, LLC (U.S.), altona Diagnostics GmbH (Germany), SA Scientific, Ltd. (U.S.), and ELITech Group (France), Coris Bioconcept SPRL (Belgium), and Mast Group Ltd.(U.K.) among others.
The emerging economies like China, India, and some Latin America countries are projected to offer significant growth opportunities for the vendors in this market with increasing prevalence of influenza, favorable reimbursement scenario, and increasing investments in the healthcare sector.
This website is secure and we do not share your personal information with any third party. Privacy Policy
Tags: Healthcare Medical Technologies
Download Free Sample